Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06250270 · ClinicalTrials.gov registry record · Early Phase 1

Effects of Casein Protein on Metabolism When Taken Prior to Sleep and in the Morning

A Early Phase 1 study of Metabolism, sponsored by Ohio University.

Active
Registry status
Early Phase 1
Development phase
15
Enrollment target
1
Study location

NCT06250270: Active Early Phase 1 study of Metabolism, sponsored by Ohio University.

NCT06250270 is a Early Phase 1 study of Metabolism that is active but no longer recruiting, run by Ohio University. The registered enrollment target is 15 participants, below the 13,265-participant average among 19 other Metabolism trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06250270, a Early Phase 1 study of Metabolism, is active but no longer recruiting, sponsored by Ohio University.

ACTIVE NOT RECRUITING
Registry status
Early Phase 1
Development phase
15 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to investigate the effect of casein protein consumption both prior to sleep as well first thing in the morning on metabolism (increase satiety and appetite, lower resting metabolic rate, and lower blood sugar levels), when compared to nighttime protein or placebo consumption alone. Protein itself is a macronutrient that not only helps the body repair itself, and play a critical role in growth, it also aids in increasing satiety and decreasing appetite. Casein protein specifically is slow digesting dairy protein which may impact the body's metabolism for a longer period than other dairy proteins such as whey. The literature demonstrates nighttime protein ingestion prior to sleep increases metabolic rate and satiety the next morning. However, there appears to be no data on the metabolic effects of protein ingested both at night and in the morning.

Primary Outcome

indirect calorimetry to measure oxygen consumption (V02) and respiratory quotient (RQ)

Conditions Studied

Interventions

  • DIETARY_SUPPLEMENT protein or placebo

Study Locations (1)

Ohio

  • Ohio University Exercise Physiology Lab - Athens

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2022-10-01
Est. Completion 2025-12-31
Phase Early Phase 1
Ohio University

51 total trials

What the registry record for NCT06250270 still lists

NCT06250270 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 13,265-participant average among 19 other Metabolism trials with a reported enrollment target (100% lower).

The record links to 1 condition, with Metabolism appearing as the primary indexed condition, and to 1 intervention - of which protein or placebo is the first listed.

NCT06250270 reports a single indexed study location in Ohio.

Frequently Asked Questions

What is clinical trial NCT06250270 about?

NCT06250270 is a clinical study titled "Effects of Casein Protein on Metabolism When Taken Prior to Sleep and in the Morning". The purpose of this study is to investigate the effect of casein protein consumption both prior to sleep as well first thing in the morning on metabolism (increase satiety and appetite, lower resting metabolic rate, and lower blood sugar levels), when compared to nighttime protein or placebo consump...

What is the current status of trial NCT06250270?

This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 15 participants. The study started on 2022-10-01. Estimated completion is 2025-12-31.

What conditions does trial NCT06250270 study?

This clinical trial studies the following conditions: Metabolism.

What interventions are being tested in trial NCT06250270?

The interventions under investigation include: protein or placebo (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT06250270?

This trial is sponsored by Ohio University, which has 51 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06250270 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Metabolism

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06250270's enrollment target sits among peer trials

15 14th of 19 higher than 6 of 19 other Metabolism trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Metabolism trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01889381 · 15 participants · Phase 2

    Human Craniomaxillofacial Allotransplantation

  • NCT02530073 · 15 participants · NA

    Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH

  • NCT02535936 · 15 participants · NA

    Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy

  • NCT02918474 · 15 participants · NA

    Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06250270, the US trial registry maintained by the National Library of Medicine. NCT06250270 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.